Avalyn Pharma Inc. cotiza a 23.74 USD y tiene una capitalización bursátil de $1.1B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused…
| Periodo | 2026-08 | 2026-06 |
|---|---|---|
| Real | $-0.98 | $-21.83 |
| Estimado | $-0.56 | $-0.81 |
| Sorpresa | -75.0% | -2595.1% |
| Métrica | AVLN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | — | -32.0% | — |
| Current Ratio | 10.19 | 2.84 | +7.35 |
| Debt / Equity | — | 0.28 | — |